Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 433-441

  Akiyama, Yasuto ^a   Maruyama, Kouji ^a   Tai, Sachiko ^a   Takikawa, Masako ^a   Ohshita, Chie ^a   Yamamoto, Akifumi ^c   Yamazaki, Naoya ^b   Kiyohara, Yoshio ^a   Yamaguchi, Ken ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

DC vaccine; Electroporation; Melanoma associated HLA A2 peptide; Metastatic melanoma; Tetramer sorting

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; INTERLEUKIN 2; MELANOMA ASSOCIATED PEPTIDE 1; MONOCLONAL ANTIBODY; PEPTIDE; T LYMPHOCYTE RECEPTOR; TETRAMER; UNCLASSIFIED DRUG; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; MART1 ANTIGEN; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL CLONING; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; JAPANESE; MELANOMA; MELANOMA CELL; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; BIOSYNTHESIS; CELL CULTURE; CELL LINE; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOLOGY; JAPAN; LYMPHOCYTE ACTIVATION; METHODOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; JAPAN; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 54849188500     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000025     Document Type: Article

References (34)

1. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
2. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
3. + progenitor-derived dendritic cell vaccine. Cancer Res 61: 6451-6458, 2001.
4. Akiyama Y, Tanosaki R, Inoue N, et al: Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 3: 4, 2005.
5. Dudley ME, Wunderlich J, Nishimura MI, et al: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24: 363-373, 2001.
6. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173, 2002.
7. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854, 2002.
8. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005.
9. Hoshino T, Seki N, Kikuchi M, et al: HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 70: 631-638, 1997.
10. Gohara R, Nakao M, Ogata Y, Isomoto H, Oizumi K and Itoh K: Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer. Jpn J Cancer Res 88: 198-204, 1997.
11. Akiyama Y, Maruyama K, Nara N, et al: Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Anticancer Res 24: 571-578, 2004.
12. Akiyama Y, Kuzushima K, Tsurumi T and Yamaguchi K: Analysis of HLA-A24-restricted CMVpp65 peptide-specific CTL with HLA-A*2402-CMVpp65 tetramer. Immunol Lett 95: 199-205, 2004.
13. Mandruzzato S, Rossi E, Bernardi F, et al: Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. J Immunol 169: 4017-4024, 2002.
14. Sensi M, Traversari C, Radrizzani M, et al: Cytotoxic T-lymphocyte clones from different patients display limited T cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 92: 5674-5678, 1995.
15. + T cells in melanoma patients. J Immunol 165: 533-538, 2000.
16. Sensi M, Salvi S, Castelli, et al: T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clone:tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence uses by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 178: 1231-1246, 1993.
17. Yee C, Savage PA, Lee PP, Davis MM and Greenberg PD: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162: 2227-2234, 1999.
18. Hishii M, Andrews D, Boyle LA, et al: In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci USA 94: 1378-1383, 1997.
19. Valmori D, Dutoit V, Schnuriger V, et al: Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 168: 4231-4240, 2002.
20. + cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother 37: 15-25, 1993.
21. Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR and Rosenberg SA: Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177: 6527-6539, 2006.
22. + T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 27: 36-47, 2004.
23. Godelaine D, Carrasco J, Lucas S, et al: Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171: 4893-4897, 2003.
24. Kass R, Bellone S, Palmieri, et al: Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat 80: 275-295, 2003.
25. Ito F, Carr A, Svensson H, Yu J, Chang AE and Li Q: Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells:implications for cell therapy in a murine model. J Immunother 26: 222-233, 2003.
26. Sili U, Huls MH, Davis AR, et al: Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother 26: 241-256, 2003.
27. Cole DJ, Wilson MC, Rivoltini L, Custer M and Nishimura MI: T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res 57: 5320-5327, 1997.
28. Romero P, Dunbar PR, Valmori D, et al: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188: 1641-1650, 1998.
29. + melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res 65: 1570-1576, 2005.
30. Hughes MS, Yu YYL, Dudley ME, et al: Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T cell effector functions. Hum Gene Ther 16: 457-472, 2005.
31. Morgan RA, Dudley ME, Wunderlich JR, et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129, 2006.
32. Tsuji T, Yasukawa M, Matsuzaki J, et al: Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106: 470-476, 2005.
33. + cells via electroporation-mediated gene delivery. Gene Ther 7: 1431-1437, 2007.
34. Chun HJ, Zheng L, Ahmad M, et al: Pleiotropic defects in lymphocytes activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419: 395-399, 2002.